Correlation of ER, PR, Her2neu and Ki67 with other Prognostic factors in Breast Carcinoma
Background:In females, breast carcinoma is the most common malignancy accounting for 23% of all malignant tumours. Various predictive and prognostic factors affect tumour progression. In addition to estrogen receptors (ER), progesterone receptors (PR) and human epidermal growth factor receptor (Her2neu), recently Ki67, a proliferative marker has been recognized as an important predictive and prognostic marker in many studies. The aim of the study was to find the correlation of ER, PR, Her2neu and Ki67 tumour markers with menopausal status, tumour size, histopathological grade, mitotic index, lymphovascular invasion and lymph node metastasis.
Methods:The present study was conducted on 50 cases of breast carcinomas. The histopathological grading of the breast carcinoma was done according to the Nottingham modification of the Bloom Richardson grading system. All the cases underwent immunohistochemistry for ER, PR, Her2neu and Ki67 expression. Correlation of ER, PR, Her2neu and Ki67 with various prognostic factors was done.
Results:The expression of ER and PR decreased as the grade of the tumour increased. Ki67 proliferative index increased as the grade of the tumour increased. Ki67 proliferative index also increased as the mitotic count increased. None of these markers showed a correlation with other prognostic factors.
Conclusion: The present study concludes that ER, PR reveals inverse relationship and Ki67 showed a direct relationship with the grade of the tumour. Increased Ki67 proliferative index was associated with increased mitotic activity and less expression of ER, PR; thus carrying a poor prognosis.
WHO Globocan 2018 World. Factsheets Cancers: Breast Factsheet. IARC; WHO [Internet] . Available From: http://gco.iarc.fr/today/data/factsheets/ cancers/20-Breast-fact-sheet.pdf.
WHO Globocan 2018 India. Factsheets Populations:India Factsheet. IARC; WHO [Internet].AvailableFrom:http://gco.iarc.fr/today/data/factsheets/populations/356-india-fact-sheets.pdf.
Moutafoff C, Coutant C, Bezu C. Prognostic and predictive factors in multifocal breast carcinoma. GynecolObstetFertil. 2011;39(7-8):425-432. doi: https://doi.org/10.1016/j.gyobfe.2011.05.001.
Baulies S, Cusido M, Gonzalez-Cao M. Hormone receptor and HER2 status: the only predictive factors of response to neoadjuvant chemotherapy in breast cancer. J ObstetGynaecol. 2015;35(5):485-489.doi: https://doi.org/10.3109/01443615.2014.968113.
Elston CW, Ellis IO. Pathological prognostic factors in breast cancer. I. The value of histological grade in breast cancer: experience from a large study with long-term follow-up. Histopathology. 1991;19(5):403-410. doi: https://doi.org/10.1111/j.1365-2559.1991.tb00229.x.
Tuffaha M.S.E, Guski H, Kristiansen G, editors. Immunohistochemistry in Tumor Diagnostics. Springer International Publishing AG 2018. Chapter 10, Markers and Immunoprofile of Breast Tumors; p.71-81. doi: https://doi.org/10.1007/978-3-319-53577-7_10.
Wolff AC, Hammond ME, Allison KH, Harvey BE, Mangu PB, Bartlett JM et al. Human Epidermal Growth Factor Receptor 2 Testing in Breast Cancer: American Society of Clinical Oncology/College of American Pathologists Clinical Practice Guideline Focused Update. J Clin Oncol. 2018 Jul 10;36(20):2105-2122.doi: https://doi.org/10.1200/JCO.2018.77.8738.
Engstrom MJ, Opdahl S, Hagen AI, Romundstad PR, Akslen LA, Haugen OA, et al. Molecular subtypes, histopathological grade and survival in a historic cohort of breast cancer patients. Breast Cancer Res Treat. 2013;140(3):463-473. doi: https://doi.org/10.1007/s10549-013-2647-2.
Kaur K, Kaur H, Gill HS, Kaur M. Evaluation of expression and correlation of ER, PR and Ki67 tumour markers in breast carcinoma. Int J Contemp Med Res. 2016;3(10):3047-3051.
Thiygarajan M, Navrathan N, Mohanapriya T, Kumar A, Singh B. Correlation between estrogen receptor, progesterone receptor, HER-2/neu status and other prognostic factors in carcinoma breast in Indian population. Int Surg J. 2015;2(4):515-22. doi: http://dx.doi.org/10.18203/2349-2902.isj20151000.
Rashmi K, Sharma J, Minhas SS, Mardi K. Hormone Receptor Status of Breast Cancer in the Himalayan Region of Northern India. Indian J Surg. 2011;73(1):9-12. doi: https://doi.org/10.1007/s12262-010-0121-5.
Desai SB, Moonim MT, Gill AK, Punia RS, Naresh KN, Chinoy RF. Hormone receptor status of breast cancer in India:a study of 798 tumours. Breast. 2000;9(5):267-270. doi: https://doi.org/10.1054/brst.2000.0134.
Tewari M, Pradhan S, Singh U, Shukla HS. Estrogen and progesterone receptor status in breast cancer: effect of oral contraceptive pills and hormone replacement therapy. Breast. 2007;16(5):540-545. doi: https://doi.org/10.1016/j.breast.2007.05.005.
Haroon S, Hashmi AA, Khurshid A, Kanpurwala MA, Mujtuba S, Malik B, Faridi N. Ki67 index in breast cancer: correlation with other prognostic markers and potential in pakistani patients. Asian Pac J Cancer Prev. 2013;14(7):4353-4358. doi: https://doi.org/10.7314/apjcp.2013.14.7.4353.
Ghosh J, Gupta S, Desai S, Shet T, Radhakrishnan S, Suryavanshi P, et al. Estrogen, progesterone and HER2 receptor expression in breast tumours of patients, and their usage of HER2-targeted therapy, in a tertiary care centre in India. Indian J Cancer. 2011;48(4):391-396. doi: https://doi.org/10.4103/0019-509X.92245.
Juneja S, Agarwal R, Agarwal D, Rana P, Singh K, Kaur S. Correlation of expression of estrogen receptor, progesterone receptor and human epidermal growth factor receptor-2 with histopathological grade in cases of carcinoma breast. Int J Contemp Med Res. 2019;6(9):I6-I11. doi: http://dx.doi.org/10.21276/ijcmr.2019.6.9.26.
Almari MN, Hamad M. Immunohistochemical evaluation of human epidermal growth factor receptor 2 and estrogen and progesterone receptors in breast carcinoma in Jordan. Breast Cancer Res. 2005;7(5):598-604. doi: https://doi.org/10.1186/bcr1200.
Puvitha RD, Shifa S. Breast Carcinoma, Receptor Status and Her-2/neu Expression Revisited. Int J Sci Stud. 2016;3(10):52-58. doi: https://doi.org/10.17354/ijss/2016/11.
Yadav R, Sen R, Chauhan P. ER, PR, HER-2/neu status and relation to clinicopathological factors in breast carcinoma. Int J Pharm Pharm Sci. 2016;8(4):287-290. Available from: https://innovareacademics.in/journals/index.php/ijpps/article/view/10776.
Faheem M, Mahmood H, Khurram M, Qasim U, Irfan J. Estrogen receptor, progesterone receptor, and Her2neu positivity and its association with tumour characteristics and menopausal status in a breast cancer cohort from northern Pakistan. Ecancermedicalscience. 2012;6:283. doi: https://doi.org/10.3332/ecancer.2012.283.
Hussein MR, Abdul Wahed SR, Abdul Wahed AR. Alterations of estrogen receptors, progesterone receptors and c-erbB2 oncogene protein expression in ductal carcinomas of the breast. Cell Bio lint. 2008;32(6):698-707. doi: https://doi.org/10.1016/j.cellbi.2008.01.007.
Inwald EC, Schalke MK, Hofsta¨dter F, Zeman F, Koller M, Gerstenhauer M et al. Ki67 is a prognostic parameter in breast cancer patients: results of a large population-based cohort of a cancer registry. Breast Cancer Res Treat. 2013;139:539–552. doi: https://doi.org/10.1007/s10549-013-2560-8.
AzizunN, Bhurgri Y, Raza F, Kayani N. Asian Comparison of ER, PR and Her2neu (C-erb B 2) reactivity pattern with histologic grade, tumour size and lymph node status in breast cancer. Pac J Can Prev. 2008;9(4):553-556.
Barrios GRM. HER2/neu incidence in early breast cancer and its correlation with others prognostic factors. J Clin Oncol. 2008;26(15):22195-22195. doi: https://doi.org/10.1200/jco.2008.26.15_suppl.22195.
Bhagat VM, Jha BM, Patel PR. Correlation of Hormonal Receptor and Her-2/neu Expression in Breast Cancer: A Study at Tertiary Care Hospital in South Gujarat. Natl J Med Res. 2012;2(3):295-298.
Antoniades K, Spector H. Correlation of Estrogen Receptor levels with Histology and Cytomorphology in Human Mammary Cancer. Am J Clin Path. 1979;71(5):497-503. doi: https://doi.org/10.1093/ajcp/71.5.497.
Shet T, Agrawal A, Nadkarni M, Palkar M, Havaldar R, Parmar V, et al. Hormone receptors over the last 8 years in a cancer referral centre in India:What was and what is? Ind J Pathol Microbiol. 2009;52(2):171-174. doi: https://doi.org/10.4103/0377-4929.48909.
Fatima S, Faridi N, Gill S. Breast cancer: steroid receptors and other prognostic indicators. J Coll Physicians Surg Pak. 2005;15(4):230-233.
Peng Y. Potential prognostic tumour biomarkers in triple-negative breast carcinoma. Beijing Da XueXue Bao Yi Xue Ban. 2012;44(5):666-672.
Han JS, Cao D, Molberg KH, Sarode VR, Rao R. Hormone receptor status rather than HER2 status is significantly associated with increased Ki67 and p53 expression in triple-negative breast carcinomas, and high expression of Ki67 but not p53 is significantly associated with axillary nodal metastasis in triple- negative and high-grade non-triple-negative breast carcinomas. Am J Clin Pathol. 2011;135(2):230-237. doi: https://doi.org/10.1309/ajcp9dv3evzuatfv.
Rhee J, Han SW, Oh DY, Kim JH, Im SA. The clinicopathologic characteristics and prognostic significance of triple-negativity in node-negative breast cancer. BMC Cancer. 2008;8:307-309. doi: https://doi.org/10.1186/1471-2407-8-307.
Naqvi SQH, Jamal Q, Mahmood RK, Zaidi SMH, Abbas F. Significance of Her2neu oncoprotein over expression on node positive invasive breast cancer. J Coll Physicians Surg Pak. 2002;12:534-537.
Soliman NA, Yussif SM. Ki67 as a prognostic marker according to breast cancer molecular subtype. Cancer Biol Med. 2016;13(4):496-504. doi: https://doi.org/10.20892/j.issn.2095-3941.2016.0066.
Nishimura R, Osako T, Okumura Y, Hayashi M, Toyozumi Y, Arima N. Ki67 as a prognostic marker according to breast cancer subtype and a predictor of recurrence time in primary breast cancer. Exp Ther Med. 2010;1(5):747-754. doi: https://doi.org/10.3892/etm.2010.133.
Yerushalmi R, Woods R, Ravdin PM, Hayes MM, Gelmon KA. Ki67 in breast cancer: prognostic and predictive potential. Lancet Oncol. 2010;11(2):174-183. doi: https://doi.org/10.1016/S1470-2045(09)70262-1.
Jones RL, Salter J, Hern RA, Nerurkar A, Parton M, Reis-Filho JS, et al. Relationship between oestrogen receptor status and proliferation in predicting response and long-term outcome to neoadjuvant chemotherapy for breast cancer. Breast Cancer Res Treat. 2010;119(2):315-323. doi: https://doi.org/10.1007/s10549-009-0329-x.
Brown RW, Allred CD, Clark GM, Osborne CK, Hilsenbeck SG. Prognostic value of Ki67 compared to S-phase fraction in axillary node-negative breast cancer. Clin Cancer Res. 1996;2(3):585-592.
Copyright (c) 2020 Author (s). Published by Siddharth Health Research and Social Welfare Society
This work is licensed under a Creative Commons Attribution 4.0 International License.